| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
Form 4: Duggan Robert W, Director
Received 500,000 shares by exercise or conversion ($530K) |
| 16 Nov 2026 |
Form 4: Zanganeh Mahkam, Director
Received 500,000 shares by exercise or conversion ($530K) |
| 16 Nov 2026 |
Form 4: Soni Manmeet Singh, Director
Received 100,000 shares by exercise or conversion ($137K) |
| 16 Nov 2026 |
8-K: Other Events
Date of Report (Date of Earliest Event Reported): November 15, 2026 |
| 04 Nov 2026 |
8-K: Other Events
We have acted as counsel to Summit Therapeutics Inc., a Delaware corporation (the “Company”), in connection with the Registration Statement on Form S-3 (File No. 333- 296642) (the “Registration Statement”) filed by the Company with the S... |
| 04 Nov 2026 | 424B7 |
| 04 Nov 2026 | 10-Q |
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
1 Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026 Recent $2 Billion Strategic Equity Investment in Summit by AstraZeneca and Summit’s Expanding Network... |
| 19 Oct 2026 | DEF 14A |
| 14 Oct 2026 |
Form 4: Anand Bhaskar, Chief Accounting Officer
Received 100,000 shares as a grant or award |
| 06 Oct 2026 | PRE 14A |
| 29 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of September 28, 2026, by and between Summit Therapeutics Inc., a Delaware corporation (the “Company”), and AstraZeneca Holdings B.V., a Dutch private limited liability co... |
| 15 Sep 2026 |
8-K: Other Events
Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients Sustained OS Improvement Seen with Longer Follow-Up in Western Patients, Consist... |
| 14 Sep 2026 |
8-K: Other Events
1 Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China Ivonescimab Reduced t... |
| 03 Sep 2026 |
8-K: Other Events
1 Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China Summit is Conducting HARMONi-... |
| 26 Aug 2026 |
8-K: Other Events
1 Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China HARMO... |
| 05 Aug 2026 |
8-K: Other Events
1 Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer HARMONi-GU1 Is First Global Registrational Clinical Trial of Ivonescimab in a Genitourinary (GU) Cancer... |
| 23 Jul 2026 |
8-K: Entry into a Material Definitive Agreement
Summit Therapeutics Inc., a Delaware corporation (the “Company”), confirms its agreement with J.P. Morgan Securities LLC, as agent and/or principal under any Terms Agreement (as defined in Section 1(a) below) (“you” or the “Agent”), with... |
| 23 Jul 2026 | 424B5 |
| 23 Jul 2026 | 10-Q |
Loading...